Rchr
J-GLOBAL ID：200901096263192228
Update date: Aug. 27, 2024
ISHIKAWA Maho
イシカワ マホ | ISHIKAWA Maho
Affiliation and department：
Job title：
Lecturer
Papers (15)：
-
Noriyoshi Iriyama, Eisaku Iwanaga, Yuta Kimura, Naoki Watanabe, Maho Ishikawa, Hitomi Nakayama, Eriko Sato, Takayuki Tabayashi, Toru Mitsumori, Tomoiku Takaku, et al. Changes in chronic myeloid leukemia treatment modalities and outcomes after introduction of second-generation tyrosine kinase inhibitors as first-line therapy: a multi-institutional retrospective study by the CML Cooperative Study Group. International Journal of Hematology. 2024. 120. 1. 60-70
-
Michihide Tokuhira, Yuta Kimura, Takayuki Tabayashi, Naoki Watanabe, Shun Tsuchiya, Tomoiku Takaku, Noriyoshi Iriyama, Eriko Sato, Tomonori Nakazato, Toru Mitsumori, et al. Clinical management of second-generation tyrosine kinase inhibitor therapy in patients with newly diagnosed chronic myeloid leukemia in the chronic phase, focusing on age and dose effects. International Journal of Hematology. 2023. 118. 2. 210-220
-
Tomoki Naoe, Akiko Saito, Nahoko Hosono, Senji Kasahara, Hideharu Muto, Kaoru Hatano, Mizuki Ogura, Taro Masunari, Masatsugu Tanaka, Kensuke Usuki, et al. Immunoreactivity to WT1 peptide vaccine is associated with prognosis in elderly patients with acute myeloid leukemia: follow-up study of randomized phase II trial of OCV-501, an HLA class II-binding WT1 polypeptide. Cancer immunology, immunotherapy : CII. 2023. 72. 8. 2865-2871
-
Shun Tsuchiya, Tomoiku Takaku, Naoki Watanabe, Noriyoshi Iriyama, Yuta Kimura, Eisaku Iwanaga, Kei-Ji Sugimoto, Toru Mitsumori, Maho Ishikawa, Tomonori Nakazato, et al. Management and Risk Factors for Pleural Effusion in Japanese Patients with Chronic Myeloid Leukemia Treated with First-line Dasatinib in Real-world Clinical Practice. Internal Medicine. 2023. 1611-1623
-
Chie Asou, Tomoya Maeda, Maho Ishikawa, Daisuke Okamura, Mika Kohri, Naoki Takahashi, Kunihiro Tsukasaki, Hirozo Sakaguchi, Tsugumi Satoh, Hidekazu Kayano, et al. Paravertebral extramedullary hematopoiesis in a case of myelodysplastic syndrome with ring sideroblasts and an SF3B1 mutation. International Journal of Hematology. 2022. 115. 6. 898-901
ｍore...
Lectures and oral presentations (8)：
-
Usefulness of new risk prediction model for VAEs in Japanese patients with CML treated with TKIs
(第85回日本血液学会学術集会 2023)
-
Outcomes of CML patients not achieving optimal response at one year of TKI treatment
(第85回日本血液学会学術集会 2023)
-
The effect of introduction of 2G-TKI as first-line therapy on CML treatment modalities and outcomes
(第85回日本血液学会学術集会 2023)
-
実臨床での慢性骨髄性白血病患者の妊娠と出産
(第85回日本血液学会学術集会 2023)
-
CML-CSGデータによる付加的染色体異常を有するCML患者の解析
(第85回日本血液学会学術集会 2023)
ｍore...
Professional career (1)：
- 大学院医学研究科内科学専攻 博士課程学位 (埼玉医科大学)
Return to Previous Page
